Jump to any asset
849 assets, updated daily
As of September 16, 2026, ResMed Inc. (RMD) trades at $229.44. CleaRank Financial AI rates it Hold with a fair value of $235.00, 2.4% above the current price. Wall Street's consensus target is $235.00 across 19 analysts. RSI at 41 is in neutral territory, and the price is above its 50-day average of $217.45.
ResMed Inc. (RMD)
ResMed Inc. NYSE
$229.44
6.450 (2.89%)
At close: Sep 15, 4:00 PM EDT
AI Analyst Consensus
59 / 100
ResMed Inc. (RMD) is currently trading at $229.44, positioned above its 50-day and 200-day moving averages ($217.45 and $227.59), indicating a generally positive technical trend. The stock's RSI is at 40.78, suggesting neutral momentum. Wall Street analysts maintain a consensus rating of Hold, with a median price target of $235.00, implying a modest 2.4% upside from current levels. The company exhibits strong fundamental metrics, including a profit margin of 26.95% and a return on equity of 24.27%, which are strong within the Healthcare sector. However, recent insider activity shows significant net selling totaling $42 million, with no insider purchases, signaling a potential lack of near-term conviction from management. The company's revenue growth has been steady, with the current quarter estimated at +4.00% year-over-year and projected to be +3.00% for the full year. Forward-looking growth estimates suggest a compound annual growth rate of approximately 12% over the next five years. Despite these positive growth prospects and strong profitability, the prevailing analyst sentiment leans towards Hold, and the notable insider selling warrants careful consideration for investors.
RMD Price Analysis
Market Metrics
Open
$226.36
Day Range
$225.12 to $234.33
Prev Close
$222.99
Volume
1.64M
52-Week Range
$180.27 to $284.87
Market Cap
$33.10B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-33%), which may indicate undervaluation or specific company headwinds.
RMD Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, RMD beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
RMD Analysis
Company's Health
4/5
12-Month Analyst Target
+2.42% Upside
Median of 19 analysts (12-month)
$235.00
AI Technical Analysis
ResMed Inc. (RMD) is currently trading above its 50-day and 200-day moving averages ($217.45 and $227.59), with its price at $229.44 sitting above the 50-day SMA of $217.45 and the 200-day SMA of $227.59. The Relative Strength Index (RSI) is at 40.78, indicating neutral momentum, and the MACD is slightly positive at 1.11. Volume has been above average recently, suggesting increased investor interest. Key support levels are suggested by the 50-day SMA and the 200-day SMA, while resistance may be found near recent highs. The chart structure shows a stock that has recovered from a dip below its 200-day SMA earlier in the year and is now consolidating. The neutral RSI suggests neither an overbought nor oversold condition, implying that the stock could move in either direction based on catalysts or broader market sentiment.
ProTips
- Monitor insider transaction activity closely, as recent net selling of $42 million by insiders may indicate a lack of near-term conviction.
- The stock's neutral RSI suggests it is neither overbought nor oversold, implying that current price levels may be a consolidation phase before a potential move.
- Given the moderate revenue growth projections, consider the competition within the medical devices sector and ResMed's ability to maintain market share.
Key Catalysts
Bearish
Significant Insider Selling Activity
Insiders have sold a net total of $42 million in ResMed Inc. (RMD) stock, with no reported insider purchases, signaling a potential lack of confidence in near-term stock appreciation.
Source: Insider TransactionsNeutral
Majority of Analysts Rate Stock as Hold
Wall Street analysts predominantly hold a 'Hold' rating on ResMed Inc. (RMD), with 11 out of 19 analysts issuing this rating, suggesting a balanced but not strongly bullish outlook.
Source: Wall Street ConsensusNeutral
Moderate Revenue Growth Projections
Current quarter revenue growth is estimated at +4.00% year-over-year, with full-year projections around +3.00%, indicating steady but not explosive growth that may limit significant price catalysts.
Source: Wall Street Revenue EstimatesBullish
Strong Profitability and ROE
ResMed Inc. (RMD) demonstrates strong profitability with a net profit margin of 26.95% and a return on equity of 24.27%, significantly outperforming sector averages and providing a strong fundamental basis.
Source: Company FundamentalsMarket Outlook
ResMed Inc. (RMD) is expected to maintain its current trading range in the near term, with a median analyst price target of $235.00 suggesting limited upside from its current price of $229.44. The company's strong profitability and solid balance sheet provide a stable foundation, but the neutral technical momentum and significant insider selling temper immediate bullish expectations. The consensus rating of Hold reflects this balanced view, indicating that while the company is fundamentally sound, there are no strong catalysts to drive substantial price appreciation in the immediate future. Potential upside could be driven by stronger-than-expected revenue growth in upcoming quarters or positive developments in new product pipelines, which are not explicitly detailed. Conversely, continued insider selling or increased competition leading to slower revenue growth could pressure the stock lower, potentially testing support levels around its 50-day and 200-day moving averages. Investors should monitor upcoming earnings reports and any shifts in analyst sentiment for directional cues.
Key Statistics
| Market Cap | 33.10B |
|---|---|
| P/E Ratio | 21.38 |
| EPS (TTM) | 10.43 |
| Dividend Yield | 1.07% |
| 52 Week High | 284.87 |
| 52 Week Low | 180.27 |
ResMed Inc. (RMD) presents a mixed valuation picture, trading at a Price-to-Earnings (P/E) ratio of 21.38, which is below the sector median of 31.9, suggesting it may be relatively undervalued compared to its peers. Its Price-to-Sales (P/S) ratio stands at 5.69, also below the sector average of 3.7, indicating a premium valuation on sales. The company demonstrates strong profitability with a net profit margin of 26.95% and an operating margin of 30.86%, significantly outperforming the sector's median Return on Equity (ROE) of 6.9%. The company's debt-to-equity ratio is a healthy 0.13, well below the sector average of 0.13, indicating a strong balance sheet with minimal leverage. While the current valuation metrics on sales appear high relative to the sector, the company's superior profitability and growth potential, as evidenced by its strong ROE and projected revenue growth, provide a solid fundamental underpinning. The key challenge remains aligning this fundamental strength with current market sentiment and analyst price targets.
Earnings & Growth Analysis
ResMed Inc. (RMD) has consistently met or slightly exceeded analyst expectations in its recent quarterly earnings reports. For the quarter ending June 2026, the company reported an Earnings Per Share (EPS) of $2.95, surpassing the estimate of $2.89 by 2.08%, although this resulted in a price decrease of 5.06%. This pattern of slight beats has been consistent across the last four reported quarters, with price reactions varying from negative to slightly positive. Revenue growth for the current quarter is estimated at +4.00% year-over-year, with projections for the next quarter at +2.00%. Full-year revenue growth is anticipated to be around +3.00%. While earnings have been stable, the moderate revenue growth suggests a maturing market or increased competition, which may be contributing to the cautious analyst sentiment.
Key Risks
A primary risk for ResMed Inc. (RMD) is the significant insider selling activity, with $42 million in sales and no reported purchases, indicating a potential lack of confidence from management regarding near-term stock performance. Also, the stock's neutral RSI and the majority of Wall Street analysts rating it as 'Hold' suggest limited near-term upside potential and a lack of strong conviction from the broader analyst community. Finally, while revenue growth is positive, it is moderate at around 4% for the current quarter, which could signal increasing competitive pressures or market saturation in its core business segments.
Technical Indicators
| RSI (14) | 40.78 |
|---|---|
| MACD | 1.11 |
| SMA 50 | 217.45 |
| SMA 200 | 227.59 |
RSI
Neutral
SMA Cross
Bearish
Price vs SMA
Bullish
MACD
Bullish
Moving averages show a lagging Death Cross (50-day: $217.45, 200-day: $227.59), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.33
Weak correlation
Nasdaq 100 (QQQ)
+0.22
Weak correlation
Bitcoin (BTC)
+0.25
Weak correlation
Gold (XAU)
+0.12
Weak correlation
Check Custom Correlation
How does any other asset move with RMD? One year of daily closes, Pearson correlation.
Try
RMD Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$227.15
Slight discount to current
Wait for small dip
Aggressive
$229.44
At current price
Enter now if confident
Risk Management
STOP LOSS
$211.25
MAX LOSS
-7.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (40.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$233.96
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$238.50
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$245.32
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for RMD is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 16, 2026.Growth of $10,000
A $10,000 investment in RMD in September 2016 would be worth about $35,594 today, compared with about $35,497 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RMD today could grow to about $26,582 by 2036 in the base case, with a bull case near $97,534 and a bear case around $7,245. Projections are statistical simulations, not guarantees.
RMD Stock Price Prediction: 2030
CleaRank's simulation projects a price near $339 for RMD by 2030 in the base case, from $229 today (1.5x over 4 years). The downside path ends near $149. These are outcomes of a Monte Carlo simulation run on RMD's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $168 | $253 | $382 |
| 2028 | $156 | $279 | $499 |
| 2029 | $151 | $308 | $627 |
| 2030 | $149 | $339 | $772 |
| 2031 | $149 | $374 | $938 |
| 2032 | $151 | $412 | $1,129 |
| 2033 | $153 | $455 | $1,350 |
| 2034 | $157 | $502 | $1,604 |
| 2035 | $161 | $553 | $1,898 |
| 2036 | $166 | $610 | $2,238 |
Method: 10,000 simulated price paths using RMD's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
RMD Insider Trading Analysis
Bought
None
No open-market buys
Sold
$42.0M
53 Transactions
Insiders
15
Active Traders
Avg Transaction
$793.1K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 5, 2024 | LEONG JUSTIN
Officer
|
Sell | 48.0K | $10.4M |
| Feb 22, 2024 | FARRELL PETER CRAIG
Director
|
Sell | 23.5K | $5.0M |
| Sep 15, 2022 | DOUGLAS ROBERT ANDREW
President
|
Sell | 17.2K | $4.0M |
| Sep 9, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.6M |
| Nov 7, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.6M |
| Oct 7, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.4M |
| May 7, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.2M |
| Aug 7, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.1M |
| Jun 7, 2024 | FARRELL MICHAEL J
Chief Executive Officer
|
Sell | 14.7K | $3.1M |
| Aug 20, 2021 | SANDERCOCK BRETT A
Chief Financial Officer
|
Sell | 10.7K | $3.0M |
Page 1 of 1
Frequently Asked Questions
Is ResMed Inc. (RMD) stock a buy right now?
ResMed Inc. (RMD) is currently rated as a Hold by Wall Street analysts, with a median price target of $235.00, implying a modest 2.4% upside from its current price of $229.44. While the company exhibits strong fundamentals and consistent earnings beats, significant insider selling and neutral technical momentum suggest caution.
What is RMD's stock price forecast for 2030?
Based on Monte Carlo simulations, ResMed Inc.'s (RMD) stock price is projected to be $339.24 in 2030 under a base case scenario. The downside projection is $149.09, and the upside projection is $771.92. These figures represent simulation outcomes, not guaranteed price targets.
How does ResMed Inc. compare to its sector averages?
ResMed Inc. (RMD) shows a P/E ratio of 21.38, which is lower than the Healthcare sector median of 31.9, but its P/S ratio of 5.69 is higher than the sector median of 3.7. The company's ROE of 24.27% significantly outperforms the sector median of 6.9%, indicating superior profitability.
What is the recent earnings performance of ResMed Inc.?
ResMed Inc. (RMD) has consistently reported earnings slightly above analyst estimates in recent quarters. For the quarter ending June 2026, EPS was $2.95 against an estimate of $2.89, a 2.08% surprise, though the stock saw a 5.06% decline post-announcement.
What are the main risks facing ResMed Inc. stock?
Key risks for ResMed Inc. (RMD) include significant insider selling totaling $42 million, a majority 'Hold' rating from Wall Street analysts, and moderate revenue growth projections. These factors suggest potential headwinds for the stock's performance.
What is the dividend yield for ResMed Inc.?
ResMed Inc. (RMD) offers a dividend yield of approximately 1.07%, with a dividend rate of $2.46.
What are the growth prospects for ResMed Inc. over the next five years?
ResMed Inc. (RMD) is projected to grow at a compound annual growth rate of approximately 12% over the next five years, according to Wall Street estimates. This growth is supported by strong fundamental metrics and consistent earnings performance.